Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03975309 · ClinicalTrials.gov registry record
DHS MIND Metabolomics
A clinical trial of Diabetes, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 417
- Enrollment target
- 1
- Study location
NCT03975309: Completed study of Diabetes, sponsored by Wake Forest University Health Sciences.
NCT03975309 is a study of Diabetes that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 417 participants, below the 3,027-participant average among 338 other Diabetes trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03975309, a study of Diabetes, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 417 participants
- Enrollment target
- 1
- Study location
Study Summary
The study team will evaluate whether metabolomic signatures of neurocognitive decline trajectories are exacerbated by the presence of type 2 diabetes mellitus (T2D) and whether these signatures contribute in part, to ethnic disparities in cognitive decline between European Americans and African Americans with T2D.
Primary Outcome
Word reading subtest to measure letter and word decoding through word recognition and letter identification. This outcome is a data pull/chart review from a previous study for some of the participants.Score range is 0-70, 70 is the best score possible.
Conditions Studied
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 417 participants |
| Start Date | 2019-09-09 |
| Est. Completion | 2023-05-23 |
What the finished NCT03975309 record still lists
NCT03975309 is an observational study that tracks outcomes without assigning an intervention. The registered 417 participants enrollment target is mid-sized for trials with a published cap, below the 3,027-participant average among 338 other Diabetes trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 0 interventions.
NCT03975309 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03975309 about?
NCT03975309 is a clinical study titled "DHS MIND Metabolomics". The study team will evaluate whether metabolomic signatures of neurocognitive decline trajectories are exacerbated by the presence of type 2 diabetes mellitus (T2D) and whether these signatures contribute in part, to ethnic disparities in cognitive decline between European Americans and African Amer...
What is the current status of trial NCT03975309?
This trial is currently completed. The enrollment target is 417 participants. The study started on 2019-09-09. Estimated completion is 2023-05-23.
What conditions does trial NCT03975309 study?
This clinical trial studies the following conditions: Diabetes.
Who is sponsoring clinical trial NCT03975309?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03975309 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03975309's enrollment target sits among peer trials
417 83rd of 338 higher than 256 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DFC 004 Biomarkers for Active Diabetic Foot Ulcers
RECRUITING
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Taste Bud-Derived Stem Cells in Humans
RECRUITING
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT06699901 · 417 participants
Antibiotic Concentrations After MassivE Transfusion Study
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI